Aurinia Pharmaceuticals Inc. (AUPH) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
AUPH Revenue Growth
Revenue Breakdown (FY 2025)
AUPH's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
AUPH Revenue Analysis (2014–2025)
As of May 6, 2026, Aurinia Pharmaceuticals Inc. (AUPH) generated trailing twelve-month (TTM) revenue of $283.1 million, reflecting exceptional growth of +28.8% year-over-year. The most recent quarter (Q4 2025) recorded $77.1 million in revenue, up 5.0% sequentially.
Looking at the longer-term picture, AUPH's 5-year compound annual growth rate (CAGR) stands at +41.4%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $283.1 million in 2025, representing a new all-time high.
Revenue diversification analysis shows AUPH's business is primarily driven by Product (96%), and License, Collaboration and Royalty Revenue (4%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including LGND (+64.8% YoY), ANIP (+43.8% YoY), and CORT (+12.2% YoY), AUPH has underperformed the peer group in terms of revenue growth. Compare AUPH vs LGND →
AUPH Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| AUPHCurrent | $283M | +28.8% | +41.4% | 37.1% | |
 LGND | $167M | +64.8% | +6.8% | -13.5% | |
 ANIP | $883M | +43.8% | +33.5% | 12.6% | |
 CORT | $761M | +12.2% | +16.6% | 5.9% | |
 GSK | $32.7B | +5.4% | +6.0% | 25.5% |
AUPH Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $283.1M | +20.4% | $250.4M | 88.5% | $104.9M | 37.1% |
| 2024 | $235.1M | +34.0% | $206.9M | 88.0% | $-4,687,000 | -2.0% |
| 2023 | $175.5M | +31.0% | $161.4M | 91.9% | $-91,691,000 | -52.2% |
| 2022 | $134.0M | +193.9% | $128.4M | 95.8% | $-111,470,000 | -83.2% |
| 2021 | $45.6M | -9.0% | $44.5M | 97.6% | $-180,735,000 | -396.3% |
| 2020 | $50.1M | +15660.4% | $50.1M | 100.0% | $-104,290,000 | -208.1% |
| 2019 | $318K | -31.3% | $318K | 100.0% | $-90,943,000 | -28598.4% |
| 2018 | $463K | +10.2% | $-40,919,000 | -8837.8% | $-56,158,000 | -12129.2% |
| 2017 | $420K | +142.8% | $419K | 99.8% | $-47,063,000 | -11205.5% |
| 2016 | $173K | -26.4% | $169K | 97.7% | $-22,814,000 | -13187.3% |
See AUPH's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AUPH Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AUPH vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAUPH — Frequently Asked Questions
Quick answers to the most common questions about buying AUPH stock.
Is AUPH's revenue growth accelerating or slowing?
AUPH revenue is accelerating at +28.8% year-over-year, exceeding the 5-year CAGR of +41.4%. TTM revenue reached $283M. Growth momentum has increased versus prior periods.
What is AUPH's long-term revenue growth rate?
Aurinia Pharmaceuticals Inc.'s 5-year revenue CAGR of +41.4% reflects the sustained expansion pattern. Current YoY growth of +28.8% is above this long-term average.
How is AUPH's revenue distributed by segment?
AUPH reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.